본문으로 건너뛰기
← 뒤로

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

사설/논평 0/5 보강
Nature medicine 📖 저널 OA 61.7% 2022: 1/1 OA 2024: 2/4 OA 2025: 17/23 OA 2026: 17/30 OA 2022~2026 2025 Vol.31(12) p. 4316
Retraction 확인
출처

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W

이 논문을 인용하기

↓ .bib ↓ .ris
APA Lovly CM, McDonald NT, et al. (2025). Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.. Nature medicine, 31(12), 4316. https://doi.org/10.1038/s41591-025-04116-5
MLA Lovly CM, et al.. "Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.." Nature medicine, vol. 31, no. 12, 2025, pp. 4316.
PMID 41266687 ↗